Skip to main content
. 2018 Apr 15;109(5):1480–1492. doi: 10.1111/cas.13569

Figure 7.

Figure 7

BLU9931 treated YTN16. (A,B) Growth of s.c. transplanted YTN16 was blunted with BLU9931 30 mg/kg b.i.d. treatment. (C,D) Growth of peritoneal dissemination of YTN16 is remarkably inhibited with BLU9931. (E,G) Microscopic appearance of peritoneal dissemination of YTN16 (E) without BLU9931 and (G) with BLU9931 treatment for 3 weeks. (F,H) Microscopic features of s.c. tumor of YTN16 (F) without BLU9931 and (H) with BLU9931 treatment for 3 weeks. YTN16 tumor under treatment with BLU9931 does not form glandular structures. (I,K) pSTAT3, (J,L) pERK, (M,N) pAKT expression in s.c. tumor of YTN16 treated (I,J,M) without or (K,L,N) with BLU9931 treatment. Expression of all 3 markers was weaker in BLU9931‐treated tumor compared to the original YTN16 tumor. (J) pErk was positive in glandular cells in the invasion front in non‐treated YTN16 tumor. (M) pAkt was positive in glands in non‐treated YTN16 throughout, and was (N) weakly positive in the few glands present in BLU9931‐treated tumor. (E‐N) Insets show high magnification